Item
2
TR-1:
NOTIFICATION
OF MAJOR INTERESTS IN
SHARES
1.
Identity of the issuer or the underlying issuer of existing shares to which
voting rights are attached:
AstraZeneca
PLC
2.
Reason for the notification (place an X inside the
appropriate bracket/s)
An
acquisition or disposal of voting rights: ( X )
An
acquisition or disposal of financial instruments which may result in the
acquisition of shares already issued to which voting rights are attached:
( )
An
event changing the breakdown of voting rights:
( )
Other
(please
specify) : ( )
3.
Full name of person(s) subject to the notification
obligation:
Capital
Group
International, Inc.
4.
Full name of shareholder(s) (if
different from 3.)
:
……………..
5.
Date of the transaction (and date on which the threshold is crossed or
reached if different):
3
December 2007
6.
Date on which issuer notified:
5
December 2007
7.
Threshold(s) that is/are crossed or reached:
3%
8.
Notified details:
……………..
A:
Voting rights attached to shares
|
Class/type
of shares if possible using the ISIN CODE
|
Situation
previous to the Triggering transaction
|
| |
|
|
| |
Number
of shares
|
Number
of voting Rights
|
|
Ordinary
Shares
|
44,074,040
|
44,074,040
|
Resulting
situation after the triggering transaction
|
Class/type
of shares if possible
using the ISIN
CODE
|
Number
of shares
|
Number
of voting rights
|
%
of
voting rights
|
| |
|
|
|
|
|
|
| |
Direct
|
Indirect
|
Direct
|
Indirect
|
Direct
|
Indirect
|
|
Ordinary
Shares
|
|
43,596,228
|
|
43,596,228
|
|
2.9873%
|
| |
|
|
|
|
|
|
B: Financial
Instruments
Resulting
situation after the triggering transaction
|
Type
of financial instrument
|
Expiration
Date
|
Exercise/Conversion
Period/ Date
|
Number
of voting rights that may be acquired if the instrument is
exercised/converted.
|
%
of
voting rights
|
|
N/A
|
|
|
|
|
Total
(A+B)
|
Number
of voting rights
|
%
of
voting rights
|
| |
|
|
43,596,228
|
2.9873%
|
9.
Chain of controlled undertakings through which the voting rights
and/or the financial instruments are effectively held, if
applicable:
……………..
Proxy
Voting:
10.
Name of the proxy holder:
……………..
11.
Number of voting rights proxy holder will cease to
hold:
……………..
12.
Date on which proxy holder will cease to hold voting
rights:
……………..
13.
Additional information:
Commencing
20
January 2007, The Capital Group Companies, Inc., no longer reports ownership
of
securities. Capital Group International, Inc. and Capital Research
and Management Company now report relevant holdings separately for the purposes
of the new DTR Handbook.
14.
Contact name:
Justin
Hoskins –
Assistant Secretary
15.
Contact telephone number:
020 7304
5112
Item
3
AstraZeneca
Presents its Global Biologics Organisation, MedImmune, at 2007 Analyst and
Investor R&D Day
AstraZeneca
(AZN)
today holds an R&D day for analysts and investors at the headquarters of its
global biologics organisation, MedImmune, in Gaithersburg, Maryland, USA,
to
present its recently expanded world-class biologics expertise. At the
meeting, which will run from 9:00 AM to 3:00 PM EST, senior leaders from
MedImmune will present the Company’s highly developed capabilities in antibody
and vaccine discovery, development, production and commercialisation within
the
broader context of AstraZeneca’s R&D activities.
"Building
a major
international presence in the research, development and commercialisation
of
biologics to complement our small molecule capabilities is key to our sustained
success,” said David Brennan, Chief Executive Officer of
AstraZeneca. “The consolidation of all our biologics capabilities
from AstraZeneca, Cambridge Antibody Technology (CAT) and MedImmune into
one
unit immediately creates one of the world’s largest biologics pipelines and
establishes us as a leader in biotechnology among our pharmaceutical
peers.”
As
part of the
event, David Mott, President and Chief Executive Officer of the newly combined
organisation that will continue to operate under the MedImmune name, will
discuss AstraZeneca’s biologics ambitions and vision and describe how MedImmune
will be operationally independent but strategically aligned within the
AstraZeneca group.
“In
MedImmune,
AstraZeneca has a world-class biologics organisation with end-to-end
capabilities from discovery through commercialisation,” said Mr. Mott. “Since
coming into AstraZeneca, we have strategically and operationally integrated
the
former Cambridge Antibody Technology group and other biologics activity within
AstraZeneca. We have brought AstraZeneca’s two pre-existing biologics
locations and approximately 300 more people under the MedImmune umbrella
to
address unmet therapeutic needs within the central nervous, gastrointestinal
and
cardiovascular systems, in addition to our historical focus on the areas
of
infectious
disease,
inflammatory disease and cancer. As a result, our biologics pipeline now
has
more than doubled in size to contain approximately 100 research projects
and
more than a dozen clinical product candidates. We also have a
stronger and more diverse discovery engine with access to a wider range of
cutting-edge technologies.
“Thanks
to these new
capabilities,” Mr Mott continued, “we have also increased our productivity
targets, including having at least three new drug candidates in pivotal trials
by 2010 and, at steady state, targeting an average of six investigational
new
drug applications for submission per year.”
Progress
in the
following key therapeutic areas will be covered at the meeting:
Infectious
Diseases:
AstraZeneca
believes
that biologics will provide novel approaches for antivirals and
antibacterials. In MedImmune, AstraZeneca has established a
significant technology base in monoclonal antibodies (MAbs) and vaccines,
which
may contribute to important new solutions for the prevention and treatment
of
infectious diseases.
While
MedImmune’s
respiratory syncytial virus (RSV) franchise has been anchored by the success
of
Synagis® (palivizumab), MedImmune is rapidly evolving its RSV-prevention efforts
through significant clinical developments for its latest anti-RSV drug
candidate, motavizumab. Today, MedImmune physicians will describe findings
from
a pivotal Phase III trial of motavizumab, which is expected to be filed under
a
biologics license application (BLA) to the U.S. Food & Drug Administration
(FDA) in early 2008. MedImmune presenters will also highlight
additional RSV programmes, including RSV vaccine candidates and a
next-generation anti-RSV MAb candidate that could follow
motavizumab.
Expanding
on its
product development experience with FluMist® (Influenza Virus Vaccine Live,
Intranasal), MedImmune also will outline its efforts to bring a vaccine to
market to help prevent pandemic influenza. MedImmune is currently engaged
in
dialogue with the U.S. government, the World Health Organisation and others
around the world on how it can help prepare for a potential pandemic
crisis.
MedImmune
currently
plans to file an application for FluMist with the European Agency for the
Evaluation of Medicinal Products (EMEA) in 2008. The
company
intends
to take
maximum advantage of AstraZeneca’s global platform to commercialise FluMist
across the world.
Respiratory
and Inflammatory Diseases:
Today,
MedImmune
scientists will describe multiple programmes currently underway to develop
targeted treatments for a variety of respiratory and inflammatory diseases.
An
important area of focus for MedImmune is the potential control of asthma
symptoms. MedImmune has a number of programmes evaluating this disease state
including ongoing Phase I and II trials studying MAbs targeting the
interleukin-5 receptor (IL-5R) and interleukin-9 (IL-9) respectively; and
a
planned Phase II trial studying a MAb targeting interleukin-13 (IL-13) in
patients with severe asthma.
MedImmune
will also
highlight data from a Phase I study assessing the safety and efficacy of
an
anti-interferon-alpha treatment, which showed consistent evidence of clinical
activity across multiple measures of disease in patients with mild-to-moderate
systemic lupus erythematosus. Furthermore, a Phase I clinical trial
for a MAb targeting the alpha subunit of the granulocyte-macrophage colony
stimulating factor receptor (GM-CSFR) is underway. The study, designed to
evaluate the safety and tolerability of single doses of this MAb in patients
with rheumatoid arthritis, is the first clinical trial in which a MAb targeting
this receptor is being investigated in this patient population.
Oncology:
Traditionally
a very
strong growth area for biologics, MedImmune anticipates developing new cancer
treatments using biological approaches with highly defined molecular targets
for
patient populations with unmet medical needs. Today MedImmune will describe
numerous oncology trials that are underway and/or planned, including those
for
IPI-504, MedImmune’s partnered drug candidate designed to inhibit heat shock
protein 90 (Hsp90). Hsp90 is an emerging cancer target, which is currently
being
evaluated as a potential treatment for three solid tumour
indications.
MedImmune
will also
discuss new data from an ongoing Phase I clinical trial of MEDI-538 (also
known
as MT103) in patients with late-stage non-Hodgkin’s
lymphoma. MEDI-538 is a recombinant single-chain bispecific T-cell
engager, or BiTE®,
molecule targeting the CD19 antigen. This candidate drug is the only
BiTE
molecule
in clinical
trials, and is currently in Phase I and II clinical development for the
treatment of various B-cell malignancies. In addition, MedImmune will
also discuss its anti-CD22 programme in Phase I development for certain
leukemias and lymphomas. Also expected in the next 24 months are Phase I
trials
of biologics candidates targeting: PDGFR-alpha, IGF, EphA2, CD19 and
CEA.
Commercialisation:
Supporting
this
strong pipeline is MedImmune's rich body of knowledge in biologics process
and
analytical development. In this area, MedImmune is led by a seasoned work
force
with experience in helping to select and optimise drug candidates from product
inception through commercialisation. As part of this process, MedImmune
investigates new pathways to disease and produces targeted, novel therapeutic
interventions. In addition, MedImmune has integrated high-productivity antibody
platforms, purification processes achieving some of the highest yields in
the
industry, and proven scale-up capabilities to meet the production demands
of a
diverse portfolio. Clinical production and analytical capability are focused
on
support for the rapidly advancing biologics portfolio at MedImmune.
Mr
Brennan
concluded, “Through the acquisition of MedImmune, Inc. and the reorganisation of
our existing biologics capabilities under the MedImmune brand, AstraZeneca
has
accelerated delivery of its biologics strategy while lowering its execution
risk. I am confident that the business model we have created — with a strong
reliance on balancing operational independence with strategic collaboration
—
will enable us to deliver on the potential of one of the largest biologics
pipelines in the industry.”
7
December
2007
Media
Enquiries:
Jamie
Lacey +1 301
398 4035
Analyst
& Investor Enquiries:
Jonathan
Hunt +44
(0) 207 304 5087
Karl
Hard +44 (0)
207 304 5322
Ed
Seage +1 302 886 4065
Jorgen
Winroth +1
212 579 0506
Peter
Vozzo + 1 301
398 4358
Notes
To
Editors
Interviews
with some
of the presenters at the R&D day can be found at:
http://www.astrazeneca.com/biologics
Broadcast
quality
footage of AstraZeneca and MedImmune products, activities and facilities
is
available from the Broadcast Centre at: http://www.thenewsmarket.com/astrazeneca
Presentations
from
today’s R&D day will be available to download at the start of the event at:
http://www.astrazeneca.com/article/511711.aspx
An
up to date development pipeline can be downloaded from: http://www.astrazeneca.com/article/511390.aspx
ABOUT
SYNAGIS
Synagis
is the only
MAb approved by the FDA to help prevent an infectious disease. Synagis is
indicated for the prevention of serious lower respiratory tract disease caused
by RSV in children at high risk of RSV disease. Synagis was approved for
use in
the United States in 1998, Europe in 1999, and Japan in 2002. Synagis is
currently available in 62 countries. Abbott has exclusive rights to Synagis
in
markets outside the United States. MedImmune promotes Synagis in the United
States.
Important
Safety Information
Globally,
prescribing information varies; refer to the individual country product label
for complete information. For U.S. safety information, visit http://www.medimmune.com/pdf/products/synagis_pi.pdf.
Synagis is
indicated for
the prevention of serious lower respiratory tract disease caused by RSV in
paediatric patients at high risk of RSV disease and is administered by
intramuscular injection. Safety and efficacy were established in infants
with
bronchopulmonary dysplasia (BPD), infants with a history of premature birth
(less than or equal to 35 weeks gestational age), and children with
hemodynamically significant congenital heart disease (CHD). Synagis has been
used in more than one million children in the U.S. since its introduction
in
1998. The first dose of Synagis
should
be
administered prior to commencement of the RSV season. Patients, including
those
who develop an RSV infection, should continue to receive monthly doses
throughout the season.
Very
rare cases
(less than one per 100,000 patients) of anaphylaxis and rare (less than one
per
1,000 patients) hypersensitivity reactions have been reported with Synagis.
Cases of anaphylaxis were reported following re-exposure to Synagis and rare
severe hypersensitivity reactions occurred on initial exposure or re-exposure.
If a severe hypersensitivity reaction occurs, therapy with Synagis should
be
permanently discontinued. If milder hypersensitivity reaction occurs, caution
should be used on re-administration of Synagis. In post-marketing reports,
very
rare cases (less than one case per 100,000 patients) of severe thrombocytopenia
(platelet count less than 50,000/microliter) have been reported.
In
clinical trials, the most common adverse events occurring at least 1 percent
more frequently in Synagis-treated patients than controls were upper respiratory
infection, otitis media, fever, and rhinitis. Cyanosis and arrhythmia were
seen
in children with CHD. There have also been post-marketing reports of injection
site reactions.
ABOUT
FLUMIST
*
FluMist is a live attenuated influenza virus vaccine indicated for active
immunization of individuals two-to-49 years of age against influenza disease
caused by influenza virus subtypes A and type B contained in the
vaccine.
FluMist
is
contraindicated in individuals with history of hypersensitivity to eggs,
egg
proteins, gentamicin, gelatin or arginine or with life-threatening reactions
to
previous influenza vaccinations, and in children and adolescents receiving
concomitant aspirin or aspirin-containing therapy.
Do
not administer FluMist to children less than 24 months of age due to an
increased risk of hospitalisation and wheezing that was observed in clinical
trials. FluMist should not be administered to any individual with
asthma and to children less than five years of age with recurrent wheezing
unless the potential benefit outweighs the potential risk. Do not
administer FluMist to individuals with severe asthma or active
wheezing.
If
Guillain-Barré syndrome has occurred with prior influenza vaccination or if an
individual is immunocompromised, the decision to give FluMist should be based
on
careful consideration of the potential benefits and risks. FluMist
should not be administered to individuals with underlying medical conditions
predisposing them to
wild-type
influenza
infection complications unless the potential benefit outweighs the potential
risk. FluMist should be given to a pregnant woman only if clearly
needed. Most
common adverse
reactions (occurring at greater than or equal to 10 percent in individuals
receiving FluMist and at least five percent greater than in placebo) are
runny
nose or nasal congestion in recipients of all ages, fever greater than 100
degrees Fahrenheit in children two-to-six years of age, and sore throat in
adults. FluMist
may not
protect all individuals receiving the vaccine. FluMist is for
intranasal administration only. Please see complete prescribing
information at http://www.medimmune.com/pdf/products/flumist_pi.pdf.
ABOUT
MEDIMMUNE
As
one of the few biotech companies in the world to have a track record of
commercial success and profitability, MedImmune has demonstrated its ability
to
bring innovative vaccines and biologics speciality products to market through
its 600-person commercial organisation in the United States. Over the last
decade, MedImmune’s revenues have grown at a compound annual rate of 36 percent
from under $50 million in 1996 to almost $1.5 billion in 2006, thanks
primarily to MedImmune’s blockbuster product, Synagis, which is the first and
only recombinantly produced MAb licensed by the FDA for prevention of an
infectious disease. Approved now in more than 60 countries, Synagis is the
standard of care for helping to prevent RSV disease in infants and young
children at high-risk for RSV.
MedImmune’s
vaccine
franchise is anchored by FDA-approved FluMist, which represents the first
licensed advance in flu vaccine technology in more than 60 years. The
first nasal mist flu vaccine approved in the U.S., FluMist is part of a platform
of technology around live, attenuated vaccines that have been developed at
MedImmune. In 2007, the FDA approved MedImmune's application to expand the
vaccine’s label to include eligible children two to five years of age, as well
as a new refrigerated formulation of FluMist. The vaccine was previously
approved by the FDA for use in children and adults five to 49 years of age
and
was stored as a frozen formulation.*
MedImmune
was also
at the forefront of the work to develop a vaccine to prevent cervical cancer
caused by human papilloma virus (HPV). The company partnered with GSK
for the completion of the clinical development and the commercialisation
of the
vaccine. In early 2005 the agreement was amended to allow
Merck, which has
also
been developing
an HPV vaccine, to be granted a sublicense to MedImmune’s intellectual
property. As a result, MedImmune receives milestone payments and
royalties on HPV vaccines marketed by both pharmaceutical
companies.
To
complement its in-house discovery and research capabilities, MedImmune has
been
among the most active biotech strategic players, having executed almost 40
significant business development, licensing and acquisition-related transactions
between 2004 and 2007.
MedImmune
strives to
provide better medicines to patients, new medical options for physicians
and
rewarding careers to employees. With approximately 3,000 employees worldwide
and
headquarters in Maryland, MedImmune is dedicated to advancing science and
medicine to help people live better lives and is wholly owned by AstraZeneca
plc
(LSE: AZN.L, NYSE: AZN). For more information, visit MedImmune's website
at
http://www.medimmune.com.
ABOUT
ASTRAZENECA
AstraZeneca
is a
major international healthcare business engaged in the research, development,
manufacture and marketing of prescription pharmaceuticals and the supply
of
healthcare services. It is one of the world's leading pharmaceutical companies
with healthcare sales of $26.47 billion and leading positions in sales of
gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and
infection products. AstraZeneca is listed in the Dow Jones Sustainability
Index
(Global) as well as the FTSE4 Good Index.
CAUTIONARY
STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
In
order to utilise the 'Safe Harbor' provisions of the United States Private
Securities Litigation Reform Act of 1995, AstraZeneca is providing the following
cautionary statement. This Review contains forward-looking statements with
respect to the research and development efforts within MedImmune, the biologics
organization within AstraZeneca. By their nature, forward-looking statements
and
forecasts involve risk and uncertainty because they relate to events and
depend
on circumstances that will occur in the future. There are a number of factors
that could cause actual results and developments to differ materially from
that
expressed or implied by these forward-looking statements. These factors include,
among other things, the risk that research and development efforts will not
yield new products that
achieve
commercial
success; the loss or expiration of patents; difficulties in the manufacturing
processes for biological products; the risk of delay to new product launches;
and the difficulties of obtaining and maintaining governmental approvals
for
products. For a more complete list of risks associated with the
AstraZeneca businesses, please refer to the AstraZeneca filings with the
Securities and Exchange Commission.
TRADEMARKS
MedImmune
and
Synagis are registered trademarks of MedImmune, Inc. and FluMist is a registered
trademark of MedImmune Vaccines, Inc. Both MedImmune, Inc. and MedImmune
Vaccines, Inc. are members of the AstraZeneca group of companies. BiTE is
a
registered trademark of Micromet, Inc.
SYN07-203
FLU07-213
-
ENDS
-
Item
4
REPURCHASE
OF SHARES IN ASTRAZENECA PLC
AstraZeneca
PLC
announced that on 10 December 2007, it purchased for cancellation 500,000
ordinary shares of AstraZeneca PLC at a price of 2299 pence per share. Upon
the
cancellation of these shares, the number of shares in issue will be
1,459,795,941.
G
H R
Musker
Company
Secretary
11
December
2007
Item
5
REPURCHASE
OF SHARES IN ASTRAZENECA PLC
AstraZeneca
PLC
announced that on 11 December 2007, it purchased for cancellation 576,000
ordinary shares of AstraZeneca PLC at a price of 2293 pence per share.
Upon the
cancellation of these shares, the number of shares in issue will be
1,459,226,059.
G
H R
Musker
Company
Secretary
12
December
2007
Item
6
AstraZeneca
Files Patent Infringement Actions in Response
to
CrestorTM ANDAs
AstraZeneca
today
announced that it has filed patent infringement actions in United States
District Court, District of Delaware, against seven generic drug manufacturers,
which have submitted Abbreviated New Drug Applications (ANDAs) for
CrestorTM.
On
1st November
2007, AstraZeneca announced its receipt of a notice-letter from Cobalt
Pharmaceuticals, Inc., notifying AstraZeneca that Cobalt had submitted
an ANDA
to the U.S. Food and Drug Administration (FDA). Cobalt’s ANDA sought approval to
market generic versions of CrestorTM tablets prior to the expiration of
patents
covering CrestorTM tablets. Cobalt’s ANDA contained a Paragraph IV certification
alleging that the U.S. patents owned or licensed by AstraZeneca, and listed
in
the FDA’s Orange Book referencing CrestorTM, were not infringed or that the
patents were otherwise invalid or unenforceable.
Since
receiving
Cobalt’s notice-letter, AstraZeneca has received similar Paragraph IV
Certification notice-letters from eight additional generic drug manufacturers.
AstraZeneca received notice letters from (1) Teva Pharmaceuticals, USA
(Teva) on
October 31, 2007; (2) Aurobindo Pharma Limited (Aurobindo) on November
5, 2007;
(3) Apotex, Inc. (Apotex) on November 6, 2007 and December 5, 2007; (4)
Par
Pharmaceutical (Par) on November 6, 2007; (5) Sandoz Inc. (Sandoz) on November
12, 2007; (6) Mylan Pharmaceuticals Inc. (Mylan) on November 15, 2007;
(7)
Glenmark Pharmaceuticals, Inc. USA (Glenmark) on November 15, 2007; and
(8) Sun
Pharmaceutical Industries Ltd. (Sun) on November 19, 2007.
Each
of the eight
additional generic drug companies has notified AstraZeneca that it has
submitted
an ANDA to the FDA seeking approval to market generic versions of CrestorTM
tablets before the expiration of the U.S. Patents owned
or
licensed by
AstraZeneca. Each notice-letter contained a Paragraph IV
certification notice alleging that one or more of the three Orange Book
listed
US patents referencing Crestor in the FDA’s Orange Book was not infringed or
otherwise invalid or unenforceable.
Based
on these
various ANDA filings and Paragraph IV certifications, on 11th December
2007
AstraZeneca filed individual patent infringement actions in United States
District Court, District of Delaware, against Aurobindo, Apotex, Cobalt,
Par,
Sandoz, Mylan, and Sun, alleging infringement of U.S. No. RE 37,314 (the
‘314
patent). AstraZeneca licenses the ‘314 patent from Shionogi & Co.
Ltd.
Summary
details of
each notice–letter are as follows:
Aurobindo
stated
that its ANDA includes a “Paragraph IV” certification, alleging that the claims
of U.S. Patent Nos. 6,316,460 B1 (the ‘460 patent), 6,858,618 (the ‘618 patent),
and the ‘314 patent are invalid, unenforceable, and/or not
infringed.
Teva
stated that its
Paragraph IV certification alleges that the ‘460 patent and the ‘618 patent are
invalid, unenforceable, and/or not infringed. AstraZeneca did not file
patent
infringement actions against Teva based on the ‘314 patent. Teva did not notify
AstraZeneca that they intended to market generic rosuvastatin calcium tablets
prior to the expiration of the ‘314 patent, which covers the active ingredient
and expires in 2016.
Apotex
stated that
its Paragraph IV certifications alleges that the ’460 patent and the ‘314 patent
are invalid, unenforceable, and/or not infringed.
Par
stated that its
Paragraph IV certification alleges that the ‘460 patent and the ‘314 patent are
invalid, unenforceable, and/or not infringed.
Sandoz
stated that
its Paragraph IV certification alleges that the ‘460 patent, the ‘618 patent,
and the ‘314 patent are invalid, unenforceable, and/or not
infringed.
Mylan
stated that
its Paragraph IV certification alleges that the ‘460 patent and the ‘314 patent
are invalid, unenforceable, and/or not infringed.
Glenmark
stated that
its Paragraph IV certification alleges that the ‘460 patent is invalid,
unenforceable, and/or not infringed. AstraZeneca did not file patent
infringement actions against Glenmark based on the ‘314 patent. Glenmark did not
notify AstraZeneca that they intended to market generic rosuvastatin calcium
tablets prior to the expiration of the ‘314 patent, which covers the active
ingredient and expires in 2016.
Sun
stated that its
Paragraph IV certification alleges that the ‘460 patent, the ‘618 patent, and
the ‘314 patent are invalid, unenforceable, and/or not infringed.
12th
December
2007
Media
Enquiries:
Steve
Brown, +44 207 304 5033 (24 hours)
Edel
McCaffrey, +44 207 304 5034 (24 hours)
Investor
Enquiries:
Jonathan
Hunt, +44 207 304 5087
Ed
Seage, +1 302 886 4065
Karl
Hard, +44 207 304 5322
Jorgen
Winroth, +1 212 579 0506
Peter
Vozzo,
(MedImmune) +1 301 398 4358
-
Ends –
Item
7
REPURCHASE
OF SHARES IN ASTRAZENECA PLC
AstraZeneca
PLC
announced that on 12 December 2007, it purchased for cancellation 660,000
ordinary shares of AstraZeneca PLC at a price of 2283 pence per share.
Upon the
cancellation of these shares, the number of shares in issue will be
1,458,566,059.
G
H R
Musker
Company
Secretary
13
December
2007
Item
8
REPURCHASE
OF SHARES IN ASTRAZENECA PLC
AstraZeneca
PLC
announced that on 13 December 2007, it purchased for cancellation 900,000
ordinary shares of AstraZeneca PLC at a price of 2284 pence per share.
Upon the
cancellation of these shares, the number of shares in issue will be
1,457,666,059.
G
H R
Musker
Company
Secretary
14
December
2007
Item
9
REPURCHASE
OF SHARES IN ASTRAZENECA PLC
AstraZeneca
PLC
announced that on 14 December 2007, it purchased for cancellation 800,000
ordinary shares of AstraZeneca PLC at a price of 2271 pence per share.
Upon the
cancellation of these shares, the number of shares in issue will be
1,456,866,319.
G
H R
Musker
Company
Secretary
17
December
2007
Item
10
TR-1:
NOTIFICATION
OF MAJOR INTERESTS IN
SHARES
1.
Identity of the issuer or the underlying issuer of existing shares
to
which voting rights are attached:
AstraZeneca
PLC
2.
Reason for the notification (place
an X inside the appropriate
bracket/s)
An
acquisition or disposal of voting rights: ( )
An
acquisition or disposal of financial instruments which may result in
the
acquisition of shares already issued to which voting rights are attached:
( )
An
event changing the breakdown of voting rights: ( )
Other
(please
specify) : ( change in issued share capital )
3.
Full name of person(s) subject to the notification
obligation:
AXA
S.A, 25 Avenue Matignon, 75008 Paris and its group companies
4.
Full name of shareholder(s) (if
different from
3.) :
……………..
5.
Date of the transaction (and date on which the threshold is crossed
or
reached if different):
17
December 2007
6.
Date on which issuer notified:
18
December 2007
7.
Threshold(s) that is/are crossed or reached:
5%
8.
Notified details:
……………..
A:
Voting rights attached to shares
|
Class/type
of shares if
possible using
the ISIN CODE
|
Situation
previous to the Triggering transaction
|
| |
|
|
| |
Number
of shares
|
Number
of voting Rights
|
|
Ordinary
Shares
|
75,243,691
|
75,243,691
|
|
American
Depositary Receipt
|
-
|
-
|
Resulting
situation after the triggering transaction
|
Class/type
of shares if
possible
using the ISIN CODE
|
Number
of shares
|
Number
of voting rights
|
%
of
voting rights
|
| |
|
|
|
|
|
| |
Direct
|
Direct
|
Indirect
|
Direct
|
Indirect
|
|
Ordinary
Shares
|
19,613,790
|
19,613,790
|
51,320,769
|
1.35
|
3.52
|
|
American
Depositary Receipt
|
-
|
-
|
-
|
-
|
-
|
B:
Financial Instruments
Resulting
situation after the triggering transaction
|
Type
of financial instrument
|
Expiration
Date
|
Exercise/Conversion
Period/ Date
|
Number
of voting rights that may be acquired if the instrument is
exercised/converted.
|
%
of
voting rights
|
|
N/A
|
|
|
|
|
Total
(A+B)
|
Number
of voting rights
|
%
of
voting rights
|
|
70,934,559
|
4.87%
|
9.
Chain of controlled undertakings through which the voting rights
and/or the financial instruments are effectively held, if
applicable:
……………..
Proxy
Voting:
10.
Name of the proxy holder:
……………..
11.
Number of voting rights proxy holder will cease to
hold:
……………..
12.
Date on which proxy holder will cease to hold voting
rights:
……………..
13.
Additional information:
……………..
14.
Contact name:
Justin
Hoskins –
Assistant Secretary
15.
Contact telephone number:
020
7304 5112